# To Evaluate Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate Cancer

> **NCT03752099** · PHASE1,PHASE2 · TERMINATED · sponsor: **Veru Inc.** · enrollment: 80 (actual)

## Conditions studied

- Metastatic Castration Resistant Prostate Cancer

## Interventions

- **DRUG:** VERU-111

## Key facts

- **NCT ID:** NCT03752099
- **Lead sponsor:** Veru Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-01-18
- **Primary completion:** 2023-03-15
- **Final completion:** 2023-03-15
- **Target enrollment:** 80 (ACTUAL)
- **Why stopped:** Administrative decision
- **Last updated:** 2023-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03752099

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03752099, "To Evaluate Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03752099. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*